Latest Videos Archives

Advanced Prostate Cancer Clinical Trials Updates

Posted by David S. Morris, MD, FACS | Nov 2022

David S. Morris, MD, FACS, of Urology Associates, PC in Nashville, Tennessee discusses advanced prostate cancer updates, including those shared recently at medical conferences including the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU) as well as several studies, namely the STAMPEDE trial, PEACE-1, ARASENS, ENZAMET, PROpel, and MAGNITUDE. Dr. Morris unpacks the takeaways, explaining that doctors should consider adding abiraterone to androgen deprivation therapy (ADT) for high-risk, non-metastatic disease; consider adding abiraterone or darolutamide for patients with mCSPC whose therapy will include using docetaxel; and consider adding poly-ADP-ribose polymerase inhibitors (PARPi) to abiraterone in patients with first-line mCRPC.

PCa Commentary | Volume 171 – November 2022

Posted by Edward Weber, MD | Nov 2022

This Commentary explores treatment regimens combining enzalutamide, apalutamide, or darolutamide with androgen deprivation for nmCRPC.

Should “Age-Related” Testosterone Deficiency (TD) Be Treated?

Posted by Abdulmaged M. Traish, PhD, MBA | Nov 2022

Abdulmaged M. Traish, MBA, PhD, Research Director at The Institute for Sexual Medicine and Emeritus Professor of Urology, both at Boston University School of Medicine in Boston, MA, discusses what he calls a fundamental question—whether age-related testosterone deficiency (TD) should be treated. He cites data demonstrating that T therapy in older men with TD produces significant health benefits. Dr. Traish questions why the U.S. Food and Drug Administration (FDA) opposes testosterone (T) therapy in older men but not in men with classical hypogonadism, concluding his talk by asserting that age-related TD does, indeed, merit treatment and by respectfully disagreeing with the FDA stance.

Current Status of PSMA PET in the United States

Posted by Phillip J. Koo, MD | Oct 2022

Philip J. Koo, MD, Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona, discusses PSMA PET and how it is poised to supplant conventional imaging techniques in the diagnosis of prostate cancer. He begins by observing the shortcomings of conventional imaging techniques such as bone scintigraphy and computed tomography. While these remain the current standard of care, they result in false negative diagnoses in most patients with biochemical recurrence, especially when the lesion is less than 1 cm with a PSA of <20 ng/ML. Dr. Koo then focuses on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging. He cites a study that found PMSA has double the detection rates over fluciclovine, with an exception of lesions in the prostate bed, indicating that different tools may be appropriate depending on lesion location. However, Dr. Koo clarifies that there currently is no data that proves the superiority of a specific PET radiopharmaceutical. Additionally, he cautions that overdiagnosis using next-generation imaging, such as PSMA PET, is likely as physicians continue to learn the benefits and drawbacks. To that end, he notes that there is a spectrum of visible lesions when using PET and a threshold below which it cannot detect disease. Dr. Koo concludes that while conventional imaging is more readily available than next-generation imaging, its limited sensitivity indicates a necessary shift to more advanced tools like PMSA PET. Similarly, since prostate cancer will advance after initial treatment in 30-50% of patients, he sees an opportunity to use PSMA PET to identify patients who require further treatment or who have metastases undetected by conventional imaging.

Optimizing Urologic Surgical Outcomes: AUA Pre-operative White Paper Recommendations

Posted by John Thomas Stoffel, MD | Oct 2022

John Thomas Stoffel, MD, Associate Professor of Urology and Chief of the Division of Neurourology and Pelvic Reconstruction within the University of Michigan Department of Urology in Ann Arbor, Michigan, outlines the purpose of the AUA quality improvement and patient safety recommendations to serve as a standardized reference for urologists as they support patient readiness for, and success after, surgery. The guidelines are broken down according to preoperative, intraoperative, and postoperative recommendations, all of which cross-thread to optimize surgical outcomes for patients.